The mission of our ACGME-accredited fellowship is to provide an environment to develop the next generation of leaders in the fields of hematology and oncology. By utilizing resources and mentors ...

Becker’s Hospital Review is pleased to release the 2016 edition of its list of 100 Hospitals and Health Systems With Great Oncology Programs. The hospitals and health systems selected for this list ...

Becker’s Hospital Review recognizes the following 30 hospitals as the nation’s leaders in cancer prevention, diagnosis, treatment and research. Barnes-Jewish Hospital/Washington University School of ...

Please provide your email address to receive an email when new articles are posted on . The Oncology Core Education and Networking program provides over 20 hours of live virtual learning. Nearly 82% ...

Kura Oncology Inc. KURA shares are up during Friday’s premarket session as the company reported promising data regarding its ...

Minimal residual disease (MRD) is becoming one of the most important response biomarkers in oncology development. Once viewed primarily as a hematologic endpoint, MRD is now influencing broader ...

Ballad Health has improved its oncology program by introducing two new advanced cancer surgical procedures: hyperthermic ...

Evidence-based clinical pathways might be able to reduce overall spending on cancer care without compromising quality. According to a new study, an oncology pathways program could save about 15% on ...

Patient navigation programs are designed to promote access to timely cancer diagnosis and care by addressing barriers to cancer care, such as challenges with health literacy, language barriers ...

The program focuses on patients who are at risk for developing heart disease before, during, or after cancer treatment.

Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, ...

CRANFORD, N.J., Oct. 7, 2025 /PRNewswire/ -- Citius Oncology, Inc. (CTOR) ("Citius Oncology" or the "Company"), a specialty biopharmaceutical company focused on the development and commercialization ...